Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.003x

Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.56 Million ≈ $521.57K USD) by net assets (CN¥1.08 Billion ≈ $158.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688488 equity financing ratio to measure how much of total assets are equity-financed.

Jiangsu Aidea Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Jiangsu Aidea Pharmaceutical Co Ltd (688488) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Xi'an Manareco New Materials Co.Ltd SHG:688550	0.043x
Revolve Group LLC NYSE:RVLV	0.024x
Vivenio Residencial SOCIMI S.A. MC:YVIV	0.018x
Tianjin Capital Environmental Protection Group Co Ltd SHG:600874	0.238x
Univest Corporation Pennsylvania NASDAQ:UVSP	0.034x
Kinh Bac City Development Share Holding Corp VN:KBC	-0.106x
ADLINK Technology Inc TW:6166	0.098x
BALTIC CLASSIF.GR LS 001 F:983	N/A

Annual Cash Flow Conversion Efficiency for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Jiangsu Aidea Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.07 Billion ≈ $156.15 Million	CN¥-37.50 Million ≈ $-5.49 Million	-0.035x	+76.21%
2023-12-31	CN¥1.13 Billion ≈ $164.70 Million	CN¥-166.22 Million ≈ $-24.32 Million	-0.148x	-91.31%
2022-12-31	CN¥1.20 Billion ≈ $175.45 Million	CN¥-92.55 Million ≈ $-13.54 Million	-0.077x	-717.31%
2021-12-31	CN¥1.31 Billion ≈ $191.66 Million	CN¥-12.37 Million ≈ $-1.81 Million	-0.009x	-122.87%
2020-12-31	CN¥1.36 Billion ≈ $198.99 Million	CN¥56.17 Million ≈ $8.22 Million	0.041x	-59.12%
2019-12-31	CN¥556.24 Million ≈ $81.39 Million	CN¥56.20 Million ≈ $8.22 Million	0.101x	+257.64%
2018-12-31	CN¥522.71 Million ≈ $76.49 Million	CN¥-33.50 Million ≈ $-4.90 Million	-0.064x	+50.96%
2017-12-31	CN¥514.09 Million ≈ $75.23 Million	CN¥-67.18 Million ≈ $-9.83 Million	-0.131x	-225.46%
2016-12-31	CN¥300.40 Million ≈ $43.96 Million	CN¥31.29 Million ≈ $4.58 Million	0.104x	--

About Jiangsu Aidea Pharmaceutical Co Ltd

SHG:688488 China Biotechnology

Market Cap

$995.03 Million

CN¥6.80 Billion CNY

Market Cap Rank

#8931 Global

#2179 in China

Share Price

CN¥16.16

Change (1 day)

+4.39%

52-Week Range

CN¥11.59 - CN¥22.16

All Time High

CN¥42.39